Abstract: Disclosed is a consumer product comprising a plurality of microcapsules dispersed in a dispersing medium. The microcapsules comprise a core and a shell around the core. The core comprises at least one functional material. The shells of the microcapsules are coated with chitosan. The dispersing medium comprises additional free chitosan. Disclosed is also a method for making such a consumer product, a method for enhancing the deposition and rinse resistance of a plurality of microcapsules dispersed in a dispersing medium and a use of chitosan for enhancing the deposition and rinse resistance of a plurality of microcapsules dispersed in a dispersing medium.

Abstract: An anhydrous and alcohol-free cosmetic product having a silky feel containing: 10 to 99, preferably 40 to 90, percent by weight dimethicone crosspolymer gel dispersed in a non-silicone fluid; and 1 to 30 percent by weight lipophilic actives, fragrance oils, or a combination thereof. The product can also contain 1 to 90 percent by weight non-silicone fluid to adjust the viscosity. This solvent can be volatile to produce a dry feel on the skin. One or more emollients can be used to moisturize the skin or to increase the miscibility of the actives and fragrance. Moreover, a preservative and some pigments can be added to the formula to preserve the product from bacteria contamination and to improve the aesthetics. The product can be used with a variety of cosmetic or fragrance products such as creams, gels, and lotions.

Abstract: The biphasic topical compositions of various embodiments comprise a Phase A including castor oil and one or more additional non-polar solvents, and a Phase B including ethanol and one or more additional polar solvents, wherein the ratio of castor oil to ethanol is about 1:1 to about 3:1; and wherein the biphasic topical composition is free of surfactants and emulsifiers. The methods include treating uneven skin tone, treating acne, lightening or brightening the skin, protecting a subject's skin from sun damage, protecting a subject's skin and scalp from the effects of aging, improving the look of the skin, improving the appearance of the skin, treating fibrotic skin conditions, treating the hair, and improving the appearance of the hair.

Abstract: Cosmetic and/or pharmaceutical compositions for promoting hair growth by modulating the expression of genes involved in the JAK-STAT signaling pathway are provided. The compositions include at least one plant lipid, preferably pataua (Oenocarpus bataua) oil. Also included are methods for promoting hair growth by modulating the expression of genes involved in the JAK-STAT signaling pathway.

Abstract: The present invention is directed to a composition comprising a water-based extract of a Commiphora plant, and method of use thereof for preventing or treating an ultra-violate (UV) radiation damage to a subject's skin.

Abstract: Provided are a cosmetic composition, a food composition, a pharmaceutical composition, and an over-the-counter (OTC) composition for skin elasticity enhancement and skin wrinkle reduction, a composition for promoting differentiation or proliferation of human adipose-derived stem cells, and a method of enhancing skin elasticity including administering the compositions to an individual other than a human, each composition including at least one substance selected from the group consisting of formononetin, emodin, artepillin C, carnosic acid, palmitamide, sodium guaiazulene sulfonate, caffeic acid, acetyl mandelic acid, laccaic acid, ubiquinone, hydroxycinnamic acid, xanthophyll, raspberry ketone, gallic acid, terpineol, sodium mannose phosphate, tropolone, glycyrrhetinic acid, lanosterol, sodium riboflavin phosphate, menadione, thioctic acid, lactoflavin, onion extract, rice bran extract, bamboo extract, carrot extract, Hibiscus extract, Magnoliae cortex extract, Aloe vera extract, and fractions of the extracts

Abstract: The invention relates to an alkaline hydrolysate of oyster meat, and to the cosmetic and dermatological uses thereof for treating signs of ageing such as wrinkles or blemishes or for improving the firmness of the skin and achieving a skin-firming effect.

Abstract: The present invention relates to Cutibacterium granulosum GENSC02 strain (KCTC 13597BP). The present invention also relates to a composition comprising the strain or its culture, and use thereof. The present invention is effective in improvement, prevention or treatment of acne, atopic dermatitis or skin inflammation by fine dust.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.

Abstract: An injectable composition in the form of a hydrogel includes water, hyaluronic acid and trehalose for inhibiting the action of hyaluronidase in the injected condition of the composition. The hyaluronic acid is of the linear type and includes sodium hyaluronate with a medium molecular weight of between 800 KDa and 2000 KDa, preferably between 1200 KDa and 1500 KDa, and sodium hyaluronate with a low molecular weight of less than 700 KDa, preferably between 200 and 400 KDa.

Abstract: The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patients cornea.

Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Abstract: A hydrogel composition and a hydrogel lens are provided. The hydrogel composition includes a hydrophilic monomer, a cross-linker, an initiator, and a rotaxane compound. In the hydrogel composition, a content range of the hydrophilic monomer is between 60 wt % and 99.85 wt %, a content range of the cross-linker is between 0.01 wt % and 1 wt %, a content range of the initiator is between 0.01 wt % and 2 wt %, and a content range of the rotaxane compound is between 0.1 wt % and 15 wt %. The rotaxane compound further includes at least one cyclic molecule and at least one linear molecule threading through the at least one cyclic molecule, and a weight ratio of the rotaxane compound relative to the hydrophilic monomer is between 1:6 and 1:99.

Abstract: The present invention relates to methods of treating gastrointestinal irregularity, as well as promoting, maintaining, and restoring gastrointestinal regularity, and maintaining healthy gut microflora in an individual. The present invention relates to methods comprising orally administering to an individual a Bacillus subtilis composition wherein the individual's gastrointestinal irregularity is treated, and/or the individual's gastrointestinal regularity and/or healthy gut microflora is promoted, maintained, and/or restored.

Abstract: Oral formulations include a polysaccharide, such as, chitosan and an anthocyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.

Abstract: The present invention regards a composition in powder form for oral inhalation, preferably for oral aspiration, comprising a mucolytic agent, preferably N-acetylcysteine. Furthermore, the present invention regards said composition for use in a method for the treatment of a mucus hypersecretion and of diseases, symptoms or disorders associated with it in a needy subject. Lastly, the present invention regards a device for administration, through inhalation route by means of oral aspiration, to said needy subject.

Abstract: A composition of food or therapeutic and other substances for administration as a cloud of droplets, the cloud comprising readily-soluble droplets having a median size range of approximately 3 microns to approximately 20 microns, or 5 microns to 10 microns, or 6 microns to 10 microns, for introduction to an animal via an ortho-nasal or retro-nasal route. Agonists or antagonists may include one or more of the following: sodium iodide, sodium chloride, magnesium chloride, capsaicin, piperine, linalool, ground cinnamon, a cannabinoid, pimento, onion, clove, thyme, ginger, menthol, or TRPV antagonists, and chocolate, Irish cream, caramel, lemon, lime, mango, raspberry, watermelon, blueberry, strawberry, mint, popcorn, meat, Resolvin D2 or nicotine. Devices for delivering compositions as an aerosol are described.

Abstract: A rheological solid personal care composition comprises a crystallizing agent, a suspension agent, an insoluble active, and an aqueous phase.

Abstract: A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.

Abstract: Compositions comprising a therapeutically effective amount of a multikinase inhibitor, such as nintedanib or axitinib or pazopanib, are provided, wherein the composition is an emulsion, such as a nanoemulsion, with lipophilic carrier (e.g., castor oil), a polyoxyl oil (e.g., polyolyl-35 castor oil), optionally with a surfactant (e.g., polysorbate 80), optionally with a cyclic oligosaccharide, such as a cyclodextrin (e.g., 2-hydroxypropyl-beta-cyclodextrin), as a solubilizer. Methods for treating ocular conditions with the compositions are also provided.

Abstract: The present invention provides compositions and methods for the inhibition of a bacterial infection. More specifically, the present invention relates to compositions and methods for the inhibition and/or treatment of a bacterial infection, particularly an infection characterized by a biofilm.

Abstract: The present disclosure relates to a cannabinoid based dry or aqueous self-emulsification system for infusing a composition with a cannabinoid. The self-emulsification system comprises: a) at least one cannabinoid in a carrier oil; b) a plurality of self-emulsifiers having a targeted combined HLB value; and c) a targeted plurality of self-emulsifiers to oil ratio; wherein b) and c) operate to solubilize at least 1 mg of the cannabinoid in 1 mL of the composition. The dry self-emulsification system is in the form of a self-emulsifiable solid which spontaneously forms an emulsion after the addition of an aqueous medium, whereas the composition spontaneously forms an emulsion upon dilution of the aqueous self-emulsification system with water.

Abstract: The present disclosure relates to a cannabinoid based emulsification system for infusing a non-aqueous composition with a cannabinoid, the emulsification system comprising: a) at least one cannabinoid in a carrier oil; b) a plurality of emulsifiers having a targeted combined HLB value; and c) a targeted plurality of emulsifiers to oil ratio; wherein b) and c) so that at least 10 wt % of the cannabinoid is solubilized in the oral cavity within 30 minutes after a subject consumes the non-aqueous composition, based on the total weight of the cannabinoid in the non-aqueous composition. Methods of making and using such emulsification systems, and cannabinoid concentrate compositions and cannabis infused non-aqueous compositions comprising such emulsification systems to form beverages, human and pet edibles and confectionaries are also encompassed by the present disclosure.

Abstract: Exosomes comprising a modified RNA are disclosed. Aspects of the disclosure further relate to methods and compositions for using exosomes comprising a modified RNA. In certain aspects, the exosomes disclosed herein may be useful in delivering a modified RNA to a cell. In certain aspects, the exosomes disclosed herein may be useful in treating or preventing a disorder in a subject. Methods and compositions for producing the disclosed exosomes are also provided.

Abstract: Described herein are lipid nanoparticles (LNPs), comprising neutral or positively charged nucleic acid mimics (NPNAMs) and optionally nucleic acids, and compositions thereof. Also described are methods of preparing LNPs comprising NPNAMs, and methods of use for intracellular gene editing. In particular, the LNPs comprising NPNAMs and optionally nucleic acids may be used in methods for the correction and/or treatment of a genetic disorder, disease, or condition in a subject.

Abstract: Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of cerebrovascular and aging-related degenerative diseases.

Abstract: Methods of preparing red blood cell mimetics and functionalized red blood cell mimetics, and methods of making and using those mimetics, are provided.

Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof.

Abstract: The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and other derivatives thereof and methods of making the same.

Abstract: Provided is a device for granulating, agglomerating, pelletising, drying and/or coating, the device including a swirl chamber, a distribution chamber, wherein the swirl chamber is separated from the distribution chamber by a base and wherein a powder to be granulated or a powder mixture to be granulated is presented in the swirl chamber, the device further including at least one agitator for thoroughly mixing the powder to be granulated or the powder mixture to be granulated and at least one addition device for a liquid, wherein the base is designed in several parts and at least one base part is horizontally and/or vertically displaceable, with the result that that the base becomes a distributor plate. Also provided is a method for granulating, agglomerating, pelletising, drying and/or coating using such a device and a base suitable for use as a distributor plate in a convective drying apparatus.

Abstract: The present invention relates to an encapsulated product that includes one or more amino acids, where the one or more amino acids are in the form of a crystal with one or more hydrophobic domains and one or more hydrophobic agents entrapped within the hydrophobic domains of the crystal of the one or more amino acids, the crystal having a hydrophilic exterior. Pharmaceutical and cosmetic compositions comprising the encapsulated product, methods of therapeutically treating a subject with the encapsulated product, as well as methods of in vitro imaging and methods of preparing an encapsulated product are also disclosed.

Abstract: The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic agents.

Abstract: The present invention relates to a pharmaceutical composition stabilized in a gelled state at at least a temperature varying from 15° C. to 40° C., comprising at least one aqueous phase gelled with at least one hydrophilic polymeric gelling agent, lipid nanocapsules comprising a liquid or semi-liquid lipid core at room temperature enveloped in a lipid envelope which is solid at room temperature, said gelled aqueous phase and nanocapsules containing at least one antibiotic, identical or different, the antibiotic in said aqueous phase being present there in the form of a solute.

Abstract: Nanoparticles comprising at least three polymers, selected independently of one another from the list comprising PLGA, PLA, TPGS, TPGS-750M, PVA, LAEOLA/PLA-PEO-PLA, and also at least one active ingredient, selected from the list comprising paclitaxel, docetaxel and SB-T-1214. The particles have a core-shell structure, the core containing the at least one active ingredient and at least two polymers, the polymers being selected independently of one another from the list comprising RG502H, RG504, PLA, LAEOLA/PLA-PEO-PLA, TPGS and TPGS-750M, the shell containing PVA and/or TPGS. The nanoparticles are nebulizable.

Abstract: The present invention explored PLGA NPs synthesis using plant extracts as surfactants by nanoprecipitation process. PLGA NPs synthesized using Camellia sinensis, Dendrocalamus hamiltonii, Ficus palmata and Rubus ellipticus leaf extracts were further explored for encapsulation, controlled and sustained release of well-known antioxidant molecule, curcumin. This plant extract based nanoprecipitation process for the synthesis of PLGA NPs can be further explored for encapsulation of many other antioxidant molecules of therapeutic importance.

Abstract: The invention relates to a method for manufacturing a nanostructured powder comprising nanocrystalline agglomerates containing active pharmaceutical ingredient (API) in its crystalline form, said method comprising (i) Preparing a first solution comprising API and an API solvent; (ii) Mixing the first solution with a second solution comprising an API antisolvent and optionally a stabilizing agent P1 to obtain a third mixture; (iii) Evaporating the third mixture until both the API solvent and the API antisolvent are evaporated, advantageously under vacuum; characterized in that when the stabilizing agent P1 is present, the third mixture has a stabilizing agent P to API weight ratio equal or less than 5, preferably less than 2. The invention also concerns a nanostructured powder and a nanosuspension.

Abstract: The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: The present invention is directed to a composition comprising aryl hydrocarbon receptor (AhR) agonists and combinations for the prevention and treatment of alopecia and hair loss, e.g. when such conditions are caused by chemotherapy, radiation therapy or hormone replacement therapy.

Abstract: An application of a GABAA receptor allosteric enhancer in medicine.

Abstract: The present disclosure provides an allosteric enhancing compound of GABAA receptors or a prodrug thereof, a method for preparing the same, and use thereof. The compound is represented by formula (1), wherein R1 and R2 are each independently selected from isopropyl or n-propyl; and when R1 is n-propyl, R2 is not isopropyl.

Abstract: The present invention provides compositions and methods for treating or preventing a gram-positive bacterial infection. In one aspect, the composition comprises at least two cannabinoids.

Abstract: The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-? inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-? inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

Abstract: Disclosed is a method for enhancing mitochondrial respiratory activity in a subject in need thereof that includes administering spermidine or a spermidine comprising extract to a subject in need thereof. The method includes the treatment and/or amelioration of mitochondrial energy disorders or diseases. The spermidine or a spermidine comprising extract can be extracted from plants or parts thereof, such as from legumes or grains or germs of legumes or grains, particularly from soya or wheat germs.

Abstract: This invention relates to high concentration solid oral dosage forms of a ketamine metabolite selected from 2R,6R-hydroxynorketamine, 2S,6S-hydroxynorketamine, R-5,6-dehydronorketamine and S-5,6-dehydronorketamine.

Abstract: The present disclosure provides a pharmaceutical composition comprising therapeutically effective amounts of cyclobenzaprine and one or more agents, and methods of treating and/or preventing sexual dysfunction.

Abstract: The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers and comprises a ?2 agonist, a propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides stable pharmaceutical composition comprising ?2 agonist, an inhaled corticosteroid and/or a long acting muscarinic antagonist. The invention also provides pharmaceutical composition for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.

Abstract: A method for maintaining a therapeutically effective concentration of endoxifen for the treatment of patient with bipolar I disorder is provided. The method includes administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the said method provides a desirable in-vivo plasma profile. The therapeutic dose monitoring is not required in a patient undergoing the said treatment. Furthermore, the method provides a significant improvement in mania assessed by the YMRS and the MADRS scores in patient undergoing the said treatment. Furthermore, the method as provides an early response time of the treatment in at least 2 days and remission time that is not more than 4 days in patient undergoing the said treatment.